Literature DB >> 26843717

Daclatasvir.

.   

Abstract

Entities:  

Year:  2015        PMID: 26843717      PMCID: PMC4674025          DOI: 10.18773/austprescr.2015.077

Source DB:  PubMed          Journal:  Aust Prescr        ISSN: 0312-8008


× No keyword cloud information.
  7 in total

Review 1.  Treating hepatitis C - what's new?

Authors:  Alex J Thompson; Jacinta A Holmes
Journal:  Aust Prescr       Date:  2015-09-18

2.  Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders.

Authors:  Donald Jensen; Kenneth E Sherman; Christophe Hézode; Stanislas Pol; Stefan Zeuzem; Victor de Ledinghen; Albert Tran; Magdy Elkhashab; Ziad H Younes; Marcelo Kugelmas; Stefan Mauss; Gregory Everson; Velimir Luketic; John Vierling; Lawrence Serfaty; Maurizia Brunetto; Jeong Heo; David Bernstein; Fiona McPhee; Delphine Hennicken; Patricia Mendez; Eric Hughes; Stephanie Noviello
Journal:  J Hepatol       Date:  2015-02-19       Impact factor: 25.083

3.  Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.

Authors:  David L Wyles; Peter J Ruane; Mark S Sulkowski; Douglas Dieterich; Anne Luetkemeyer; Timothy R Morgan; Kenneth E Sherman; Robin Dretler; Dawn Fishbein; Joseph C Gathe; Sarah Henn; Federico Hinestrosa; Charles Huynh; Cheryl McDonald; Anthony Mills; Edgar Turner Overton; Moti Ramgopal; Bruce Rashbaum; Graham Ray; Anthony Scarsella; Joseph Yozviak; Fiona McPhee; Zhaohui Liu; Eric Hughes; Philip D Yin; Stephanie Noviello; Peter Ackerman
Journal:  N Engl J Med       Date:  2015-07-21       Impact factor: 91.245

4.  All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.

Authors:  Michael Manns; Stanislas Pol; Ira M Jacobson; Patrick Marcellin; Stuart C Gordon; Cheng-Yuan Peng; Ting-Tsung Chang; Gregory T Everson; Jeong Heo; Guido Gerken; Boris Yoffe; William J Towner; Marc Bourliere; Sophie Metivier; Chi-Jen Chu; William Sievert; Jean-Pierre Bronowicki; Dominique Thabut; Youn-Jae Lee; Jia-Horng Kao; Fiona McPhee; Justin Kopit; Patricia Mendez; Misti Linaberry; Eric Hughes; Stephanie Noviello
Journal:  Lancet       Date:  2014-07-28       Impact factor: 79.321

5.  All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.

Authors:  David R Nelson; James N Cooper; Jacob P Lalezari; Eric Lawitz; Paul J Pockros; Norman Gitlin; Bradley F Freilich; Ziad H Younes; William Harlan; Reem Ghalib; Godson Oguchi; Paul J Thuluvath; Grisell Ortiz-Lasanta; Mordechai Rabinovitz; David Bernstein; Michael Bennett; Trevor Hawkins; Natarajan Ravendhran; Aasim M Sheikh; Peter Varunok; Kris V Kowdley; Delphine Hennicken; Fiona McPhee; Khurram Rana; Eric A Hughes
Journal:  Hepatology       Date:  2015-03-10       Impact factor: 17.425

6.  Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.

Authors:  Hiromitsu Kumada; Yoshiyuki Suzuki; Kenji Ikeda; Joji Toyota; Yoshiyasu Karino; Kazuaki Chayama; Yoshiiku Kawakami; Akio Ido; Kazuhide Yamamoto; Koichi Takaguchi; Namiki Izumi; Kazuhiko Koike; Tetsuo Takehara; Norifumi Kawada; Michio Sata; Hidetaka Miyagoshi; Timothy Eley; Fiona McPhee; Andrew Damokosh; Hiroki Ishikawa; Eric Hughes
Journal:  Hepatology       Date:  2014-04-01       Impact factor: 17.425

7.  Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.

Authors:  Mark S Sulkowski; David F Gardiner; Maribel Rodriguez-Torres; K Rajender Reddy; Tarek Hassanein; Ira Jacobson; Eric Lawitz; Anna S Lok; Federico Hinestrosa; Paul J Thuluvath; Howard Schwartz; David R Nelson; Gregory T Everson; Timothy Eley; Megan Wind-Rotolo; Shu-Pang Huang; Min Gao; Dennis Hernandez; Fiona McPhee; Diane Sherman; Robert Hindes; William Symonds; Claudio Pasquinelli; Dennis M Grasela
Journal:  N Engl J Med       Date:  2014-01-16       Impact factor: 91.245

  7 in total
  2 in total

Review 1.  Asunaprevir.

Authors: 
Journal:  Aust Prescr       Date:  2015-11-19

Review 2.  Sofosbuvir with velpatasvir.

Authors: 
Journal:  Aust Prescr       Date:  2017-08-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.